Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
635.45
+6.72 (1.07%)
At close: Jun 5, 2026, 4:00 PM EDT
635.00
-0.45 (-0.07%)
After-hours: Jun 5, 2026, 7:53 PM EDT
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Regeneron Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $833.31. The average 1-year stock price forecast is 31.14% higher than the current stock price, while the lowest is $641 (+0.87%) and the highest is $1,000 (+57.37%).
Price Target: $833.31 (+31.14%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 18 | 18 | 16 | 16 |
| Buy | 2 | 2 | 4 | 4 | 5 | 5 |
| Hold | 8 | 8 | 7 | 7 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 27 | 29 | 29 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $855 | Buy | Maintains | $855 | +34.55% | Jun 2, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $730 | Buy | Maintains | $730 | +14.88% | May 21, 2026 |
| Scotiabank | Scotiabank | Hold Maintains $770 | Hold | Maintains | $770 | +21.17% | May 19, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $1,057 → $875 | Buy | Maintains | $1,057 → $875 | +37.70% | May 19, 2026 |
| Wolfe Research | Wolfe Research | Buy Reiterates $860 | Buy | Reiterates | $860 | +35.34% | May 18, 2026 |
Financial Forecast
Revenue This Year
15.88B
from 14.34B
Increased by 10.72%
Revenue Next Year
17.55B
from 15.88B
Increased by 10.53%
EPS This Year
46.25
from 44.31
Increased by 4.37%
EPS Next Year
53.77
from 46.25
Increased by 16.27%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.2B | ||
| Avg | 15.9B | ||
| Low | 14.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 19.8% | ||
| Avg | 10.7% | ||
| Low | 2.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 46.25 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 4.4% | ||
| Low | - |